Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05673811 · ClinicalTrials.gov registry record · Phase 2

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

A Phase 2 study of Pancreatic Adenocarcinoma and Metastatic, sponsored by Theriva Biologics SL.

Completed
Registry status
Phase 2
Development phase
112
Enrollment target
17
Study locations

NCT05673811 is a Phase 2 study of Pancreatic Adenocarcinoma and Metastatic that has completed, run by Theriva Biologics SL. The registered enrollment target is 112 participants, below the 99,463-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 17 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05673811, a Phase 2 study of Pancreatic Adenocarcinoma and Metastatic, has completed, sponsored by Theriva Biologics SL.

COMPLETED
Registry status
Phase 2
Development phase
112 participants
Enrollment target
17
Study locations

Study Summary

A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer

Conditions Studied

Pancreatic Adenocarcinoma Metastatic

Interventions

  • DRUG Gemcitabine
  • DRUG Nab-paclitaxel
  • GENETIC VCN-01

Study Locations (17)

Other

  • Hospital Universitari Vall d'Hebron - Barcelona
  • Hospital Gregorio Marañon - Madrid
  • Hospital Universitario Ramon y Cajal - Madrid
  • Hospital Universitario 12 de Octubre - Madrid
  • Hospital Universitario Virgen de la Victoria - Málaga
  • Hospital General Univesitario de Valencia - Valencia
  • Hospital Miguel Servet - Zaragoza

California

  • Hoag Memorial Hospital Presbyterian - Newport Beach
  • University of California - Davis Cancer Center - Sacramento

Kentucky

  • University of Louisville - Brown Cancer Center - Louisville

New York

  • Weill Cornell Medical Center - New York

Ohio

  • Martha Morehouse Tower - Columbus

Utah

  • Huntsman Cancer Institute, University of Utah - Salt Lake City

Virginia

  • Virginia Cancer Specialists - Fairfax

Andalusia

  • Hospital Universitario Virgen del Rocío - Seville

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2023-01-10
Est. Completion 2025-03-28
Phase Phase 2

Sponsor

Theriva Biologics SL

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05673811

The ClinicalTrials.gov registry entry for NCT05673811 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99,463-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The listed sponsor is Theriva Biologics SL, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.

NCT05673811 reports 17 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Kentucky.

Frequently Asked Questions

What is clinical trial NCT05673811 about?

NCT05673811 is a clinical study titled "Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer". A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer

What is the current status of trial NCT05673811?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2023-01-10. Estimated completion is 2025-03-28.

What conditions does trial NCT05673811 study?

This clinical trial studies the following conditions: Pancreatic Adenocarcinoma, Metastatic.

What interventions are being tested in trial NCT05673811?

The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), VCN-01 (GENETIC).

Who is sponsoring clinical trial NCT05673811?

This trial is sponsored by Theriva Biologics SL, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05673811 being conducted?

This trial has 17 study locations across California, Kentucky, New York, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Adenocarcinoma

All registered trials for this condition

Metastatic

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.